CSPC Included in CPIE 100 for Five Consecutive Years

On October 11, the list of "2023 Top 100 Chinese Pharmaceutical Innovation Enterprises" (hereafter referred to as "CPIE 100") was released. It was generated by Healthcare Executive Magazine based on a "three-dimensional, four-index" evaluation system, using data from Clarivate's Derwent Innovation patent data and Cortellis™ competitive intelligence and clinical trial data after data selection, integration, and analysis over several months. 

CSPC has made it into this list for five consecutive years, maintaining a stable position at the top tier. 

Healthcare Executive Magazine evaluated the enterprises based on three dimensions: innovation foundation, innovation process, and innovation achievements, and based on four indexes: number of granted patents, total patent citations, the number of clinical trials, and the number of innovative drugs approved and marketed, which provide a comprehensive reflection of China's pharmaceutical innovation strength. The data shows that in 2023, the CPIE 100 companies recorded a proportion of 61.26% and 68.58% in terms of the number of authorized patents and total patent citations, respectively; and 55%, 74%, and 75% for the Phases I, II, and III clinical trials, respectively. 

This marks the fifth time Healthcare Executive Magazine has published the CPIE 100 list. It is also the fifth consecutive year that CSPC has been included in this list, consistently maintaining a leading position within the top tier. This achievement establishes CSPC as a strong and enduring force in the field of innovative pharmaceuticals in China. This is also in alignment with the longstanding and relentless efforts of the CSPC in innovation for years. 

In 2022, CSPC remained steadfast in its commitment to innovation-driven goals and invested approximately 4 billion yuan in research and development. In the first half of 2023, CSPC invested an additional 2.304 billion yuan in research and development, representing a year-on-year growth of 22.3%, maintaining a high growth rate in research and development expenditure. In 2022-2023, CSPC successively marketed several innovative drugs, including Jinlitai (Narlumosbart Injection, a National Class 1 New Drug), Duentai (China's first mRNA vaccine), Duoenyi (China's first domestically-produced Irinotecan Hydrochloride Liposome Injection), Duoenda (Mitoxantrone Hydrochloride Liposome Injection, the world's first Mitoxantrone nanomedicine), and Copiktra (Duvelisib Capsules, China's first PI3K inhibitor). 

Moreover, CSPC currently has over 300 drugs under research, more than 60 of which are in clinical trials or the application process. It is anticipated that in the next five years, over 40 innovative drugs and new pharmaceutical formulations, along with more than 60 generic drugs, will be marketed. They will include: 

Mitoxantrone Hydrochloride Liposome, Docetaxel Albumin Nanoparticles, Sirolimus Albumin Nanoparticles, Cisplatin Polymer Micelles, and Paclitaxel Albumin Nanoparticles (quick-dissolving), all developed by the nanotechnology platform; 

Ultra-long-acting GLP1-IgD/IgG4 Fc fusion protein in the metabolism field;

Global novel CX43 inhibitory and activating antibodies;

Coupled Novel ADCs and ISACs based on enzymatic method;

CD20/CD47 bispecific antibody products based on a novel asymmetric structure;

Multivalent mRNA vaccines against SARS-CoV-2 mutants

Small nucleic acid drugs, administered once per half a year.

These are heavyweight products with global patents and significant market value. The marketing of these new products will support the group's high-quality growth in the future.